| 1 | Leigh syndrome, nuclear | Enrichment | ATP5PO, IARS2, MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6, NDUFA13, NDUFV1 | 10.84 |
| 2 | Mitochondrial myopathy with reversible cytochrome c oxidase deficiency | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 10.78 |
| 3 | Mitochondrial myopathy, infantile, transient | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 10.64 |
| 4 | Mitochondrial disease | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6, NDUFS1, OPA1, SPG7, TWNK, UQCRC2 | 10.61 |
| 5 | Leigh disease | Enrichment | ATP5PO, IARS2, MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6, NDUFA13, NDUFS1, NDUFV1 | 10.55 |
| 6 | Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6, NDUFS1 | 9.67 |
| 7 | Leber hereditary optic neuropathy, modifier of | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6 | 8.21 |
| 8 | Leigh syndrome, mitochondrial | Enrichment | MT-ATP6, MT-ND1, MT-ND2, MT-ND5, MT-ND6 | 8.15 |
| 9 | Mitochondrial complex v deficiency, mitochondrial type 1 | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 7.66 |
| 10 | Neuropathy, ataxia, and retinitis pigmentosa | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 7.66 |
| 11 | Striatonigral degeneration, infantile, mitochondrial | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 7.66 |
| 12 | Camptodactyly of fingers | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 7.66 |
| 13 | Optic atrophy plus syndrome | Enrichment | ACO2, AFG3L2, MT-ND1, MT-ND6, OPA1, PMPCA, SPG7 | 7.66 |
| 14 | Mitochondrial complex i deficiency, nuclear type 1 | Enrichment | MT-ND1, MT-ND2, NDUFA13, NDUFS1, NDUFS3, NDUFV1 | 6.61 |
| 15 | Hypertelorism | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 5.77 |
| 16 | Cox deficiency, benign infantile mitochondrial myopathy | Enrichment | COX4I1, COX5A, MT-CO1, MT-CO2 | 5.65 |
| 17 | Leber optic atrophy and dystonia | Enrichment | MT-ND1, MT-ND5, MT-ND6 | 5.47 |
| 18 | Leber plus disease | Enrichment | MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5, MT-ND6 | 5.32 |
| 19 | Mitochondrial complex iv deficiency, nuclear type 1 | Enrichment | COX4I1, MT-CO1, MT-CO2, NDUFV1 | 4.81 |
| 20 | Alzheimer disease mitochondrial | Enrichment | MT-ND1, MT-ND2 | 4.30 |
| 21 | Lactic acidosis | Enrichment | ATP5F1A, DLD, NDUFA13 | 4.14 |
| 22 | Mitochondrial complex v deficiency, nuclear type 5 | Enrichment | MT-ND5, NDUFV1 | 3.83 |
| 23 | Pyruvate dehydrogenase e1-alpha deficiency | Enrichment | LONP1, PDHA1 | 3.53 |
| 24 | Autosomal recessive isolated optic atrophy | Enrichment | ACO2, YME1L1 | 3.53 |
| 25 | Hyperinsulinemic hypoglycemia, familial, 1 | Enrichment | GLUD1, HADH | 3.14 |
| 26 | Deafness, nonsyndromic sensorineural, mitochondrial | Enrichment | MT-CO1, MT-ND1 | 3.14 |
| 27 | Parkinson disease 6, autosomal recessive early-onset | Enrichment | MT-ND5, MT-ND6 | 3.14 |
| 28 | Nonsyndromic genetic hyperinsulinism | Enrichment | GLUD1, HADH | 3.14 |
| 29 | Retinitis pigmentosa | Enrichment | IDH3A, MT-ATP6, MT-CO1, MT-CO2, MT-ND1, MT-ND2, MT-ND5 | 3.12 |
| 30 | Isolated atp synthase deficiency | Enrichment | ATP5F1A, MT-ATP6 | 2.87 |
| 31 | Perrault syndrome 2 | Enrichment | CLPP, TWNK | 2.76 |
| 32 | Dystonia | Enrichment | AFG3L2, MT-ND1, MT-ND6 | 2.72 |
| 33 | Optic nerve disease | Enrichment | MT-ATP6, MT-ND1 | 2.67 |
| 34 | Familial colorectal cancer | Enrichment | MT-CO1, MT-CO2 | 2.67 |
| 35 | Rare mitochondrial non-syndromic sensorineural deafness | Enrichment | MT-CO1, MT-ND1 | 2.67 |
| 36 | Isolated complex iii deficiency | Enrichment | UQCRC2, UQCRQ | 2.58 |
| 37 | Alzheimer's disease | Enrichment | APP, MT-ND1 | 2.43 |
| 38 | Perrault syndrome 1 | Enrichment | CLPP, TWNK | 2.25 |
| 39 | Alzheimer disease, familial, 1 | Enrichment | APP, MT-ND1 | 2.20 |
| 40 | Sudden infant death syndrome | Enrichment | MT-ND1, PDHA1 | 2.20 |
| 41 | Hereditary leiomyomatosis and renal cell cancer | Enrichment | FH | 2.15 |
| 42 | 3-hydroxyacyl-coa dehydrogenase deficiency | Enrichment | HADH | 2.15 |
| 43 | D-lactic aciduria with gout | Enrichment | LDHD | 2.15 |
| 44 | Oxoglutarate dehydrogenase deficiency | Enrichment | OGDH | 2.15 |
| 45 | Hsd10 mitochondrial disease | Enrichment | HSD17B10 | 2.15 |
| 46 | Ataxia and polyneuropathy, adult-onset | Enrichment | MT-ATP6 | 2.15 |
| 47 | Spastic paraplegia 9a, autosomal dominant | Enrichment | ALDH18A1 | 2.15 |
| 48 | Epilepsy, familial adult myoclonic, 2 | Enrichment | STARD7 | 2.15 |
| 49 | Myoglobinuria, recurrent | Enrichment | MT-CO1 | 2.15 |
| 50 | Codas syndrome | Enrichment | LONP1 | 2.15 |
| 51 | Myopathy, lactic acidosis, and sideroblastic anemia 3 | Enrichment | MT-ATP6 | 2.15 |
| 52 | Parkinson disease 13, autosomal dominant | Enrichment | HTRA2 | 2.15 |
| 53 | Fumarase deficiency | Enrichment | FH | 2.15 |
| 54 | Isobutyryl-coa dehydrogenase deficiency | Enrichment | ACAD8 | 2.15 |
| 55 | 2-methylbutyryl-coa dehydrogenase deficiency | Enrichment | ACADSB | 2.15 |
| 56 | Optic atrophy 13 with retinal and foveal abnormalities | Enrichment | SSBP1 | 2.15 |
| 57 | Spastic ataxia 5, autosomal recessive | Enrichment | AFG3L2 | 2.15 |
| 58 | 2,4-dienoyl-coa reductase deficiency | Enrichment | NADK2 | 2.15 |
| 59 | Succinyl-coa:3-oxoacid-coa transferase deficiency | Enrichment | OXCT1 | 2.15 |
| 60 | Cutis laxa, autosomal recessive, type iiia | Enrichment | ALDH18A1 | 2.15 |
| 61 | Even-plus syndrome | Enrichment | HSPA9 | 2.15 |
| 62 | Anemia, sideroblastic, 4 | Enrichment | HSPA9 | 2.15 |
| 63 | Retinitis pigmentosa 90 | Enrichment | IDH3A | 2.15 |
| 64 | Spastic paraplegia 9b, autosomal recessive | Enrichment | ALDH18A1 | 2.15 |
| 65 | Maple syrup urine disease, type ii | Enrichment | DBT | 2.15 |
| 66 | Mitochondrial complex i deficiency, nuclear type 8 | Enrichment | NDUFS3 | 2.15 |
| 67 | Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 | Enrichment | TWNK | 2.15 |
| 68 | Mitochondrial complex v deficiency, nuclear type 4b | Enrichment | ATP5F1A | 2.15 |
| 69 | Oncocytoma | Enrichment | MT-ND6 | 2.15 |
| 70 | Syndromic x-linked intellectual disability type 10 | Enrichment | HSD17B10 | 2.15 |
| 71 | Spinocerebellar ataxia 28 | Enrichment | AFG3L2 | 2.15 |
| 72 | Cutis laxa, autosomal dominant 3 | Enrichment | ALDH18A1 | 2.15 |
| 73 | Alcohol sensitivity, acute | Enrichment | ALDH2 | 2.15 |
| 74 | Perrault syndrome 5 | Enrichment | TWNK | 2.15 |
| 75 | Leiomyoma cutis | Enrichment | FH | 2.15 |
| 76 | Hyperinsulinemic hypoglycemia, familial, 6 | Enrichment | GLUD1 | 2.15 |
| 77 | Gemistocytic astrocytoma | Enrichment | IDH2 | 2.15 |
| 78 | Protoplasmic astrocytoma | Enrichment | IDH2 | 2.15 |
| 79 | Cerebral amyloid angiopathy, app-related | Enrichment | APP | 2.15 |
| 80 | Spastic paraplegia 13, autosomal dominant | Enrichment | HSPD1 | 2.15 |
| 81 | D-2-hydroxyglutaric aciduria 2 | Enrichment | IDH2 | 2.15 |
| 82 | Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia | Enrichment | IARS2 | 2.15 |
| 83 | Dominant hereditary optic atrophy | Enrichment | OPA1 | 2.15 |
| 84 | Neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities | Enrichment | SHMT2 | 2.15 |
| 85 | Spastic ataxia 5 | Enrichment | AFG3L2 | 2.15 |
| 86 | Pigmented nodular adrenocortical disease, primary, 4 | Enrichment | PRKACA | 2.15 |
| 87 | Autosomal recessive cutis laxa type iii | Enrichment | ALDH18A1 | 2.15 |
| 88 | Combined oxidative phosphorylation deficiency 22 | Enrichment | ATP5F1A | 2.15 |
| 89 | Developmental and epileptic encephalopathy 51 | Enrichment | MDH2 | 2.15 |
| 90 | Parkinson disease 22, autosomal dominant | Enrichment | CHCHD2 | 2.15 |
| 91 | Protoporphyria, erythropoietic, 2 | Enrichment | CLPX | 2.15 |
| 92 | Fumarate hydratase deficiency | Enrichment | FH | 2.15 |
| 93 | Mixed oligodendroglioma-astrocytoma | Enrichment | IDH2 | 2.15 |
| 94 | Optic atrophy 11 | Enrichment | YME1L1 | 2.15 |
| 95 | Cardioacrofacial dysplasia 1 | Enrichment | PRKACA | 2.15 |
| 96 | Anaplastic oligoastrocytoma | Enrichment | IDH2 | 2.15 |
| 97 | Mitochondrial complex iv deficiency, nuclear type 20 | Enrichment | COX5A | 2.15 |
| 98 | Mitochondrial complex v deficiency, nuclear type 4a | Enrichment | ATP5F1A | 2.15 |
| 99 | Combined oxidative phosphorylation deficiency 43 | Enrichment | TIMM22 | 2.15 |
| 100 | Combined oxidative phosphorylation deficiency 45 | Enrichment | MRPL12 | 2.15 |
| 101 | Mitochondrial complex iv deficiency, nuclear type 16 | Enrichment | COX4I1 | 2.15 |
| 102 | Hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2 | Enrichment | ATP5F1B | 2.15 |
| 103 | Mitochondrial dna depletion syndrome, hepatocerebrorenal form | Enrichment | TWNK | 2.15 |
| 104 | Fibrillary astrocytoma | Enrichment | IDH2 | 2.15 |
| 105 | Acute myocardial infarction | Enrichment | IDH2 | 2.15 |
| 106 | Lateral sclerosis | Enrichment | SPG7 | 2.15 |
| 107 | Non-classic congenital lipoid adrenal hyperplasia due to star deficency | Enrichment | STAR | 2.15 |
| 108 | Maternally-inherited spastic paraplegia | Enrichment | MT-ATP6 | 2.15 |
| 109 | Classic congenital lipoid adrenal hyperplasia due to star deficency | Enrichment | STAR | 2.15 |
| 110 | Autosomal dominant complex spastic paraplegia type 9b | Enrichment | ALDH18A1 | 2.15 |
| 111 | Hereditary paraganglioma-pheochromocytoma syndromes | Enrichment | FH, MDH2 | 2.02 |
| 112 | Charcot-marie-tooth disease, demyelinating, type 1a | Enrichment | MT-ATP6 | 1.85 |
| 113 | Leiomyoma, uterine | Enrichment | FH | 1.85 |
| 114 | Cerebral amyloid angiopathy, cst3-related | Enrichment | APP | 1.85 |
| 115 | Optic atrophy 1 | Enrichment | OPA1 | 1.85 |
| 116 | Behr syndrome | Enrichment | OPA1 | 1.85 |
| 117 | Alpha-methylacetoacetic aciduria | Enrichment | ACAT1 | 1.85 |
| 118 | Deafness, sensorineural, autosomal-mitochondrial type | Enrichment | MT-ND1 | 1.85 |
| 119 | Hydrocephalus, normal-pressure, 1 | Enrichment | PMPCA | 1.85 |
| 120 | Dihydrolipoamide dehydrogenase deficiency | Enrichment | DLD | 1.85 |
| 121 | Cardiomyopathy, infantile hypertrophic | Enrichment | MT-ATP6 | 1.85 |
| 122 | Toe syndactyly, telecanthus, and anogenital and renal malformations | Enrichment | STAR | 1.85 |
| 123 | Leukodystrophy, hypomyelinating, 4 | Enrichment | HSPD1 | 1.85 |
| 124 | Porphyria, acute intermittent | Enrichment | ACO2 | 1.85 |
| 125 | Thyroid carcinoma, hurthle cell | Enrichment | NDUFA13 | 1.85 |
| 126 | Hyperinsulinemic hypoglycemia, familial, 4 | Enrichment | HADH | 1.85 |
| 127 | Protoporphyria, erythropoietic, 1 | Enrichment | FECH | 1.85 |
| 128 | Leukoencephalopathy, cystic, without megalencephaly | Enrichment | NDUFA2 | 1.85 |
| 129 | Methemoglobinemia due to deficiency of methemoglobin reductase | Enrichment | DLD | 1.85 |
| 130 | Mitochondrial dna depletion syndrome 14 | Enrichment | OPA1 | 1.85 |
| 131 | Optic atrophy 8 | Enrichment | OPA1 | 1.85 |
| 132 | Pyruvate dehydrogenase e1-beta deficiency | Enrichment | PDHB | 1.85 |
| 133 | Glycogen storage disease iii | Enrichment | AFG3L2 | 1.85 |
| 134 | Spastic paraplegia 79b, autosomal recessive | Enrichment | SPG7 | 1.85 |
| 135 | Amed syndrome, digenic | Enrichment | ALDH2 | 1.85 |
| 136 | Optic atrophy 12 | Enrichment | AFG3L2 | 1.85 |
| 137 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 | Enrichment | SPG7 | 1.85 |
| 138 | Spastic paraplegia 5a, autosomal recessive | Enrichment | ALDH18A1 | 1.85 |
| 139 | Combined oxidative phosphorylation deficiency 36 | Enrichment | MRPS2 | 1.85 |
| 140 | Perrault syndrome 3 | Enrichment | CLPP | 1.85 |
| 141 | 3-hydroxy-3-methylglutaryl-coa synthase-2 deficiency | Enrichment | HMGCS2 | 1.85 |
| 142 | Charcot-marie-tooth disease type 1a | Enrichment | MT-ATP6 | 1.85 |
| 143 | Oligodendroglioma | Enrichment | IDH2 | 1.85 |
| 144 | Depressive disorder | Enrichment | TWNK | 1.85 |
| 145 | Fibrolamellar carcinoma | Enrichment | PRKACA | 1.85 |
| 146 | Acute porphyria | Enrichment | ACO2 | 1.85 |
| 147 | Autosomal recessive sideroblastic anemia | Enrichment | HSPA9 | 1.85 |
| 148 | Anaplastic oligodendroglioma | Enrichment | IDH2 | 1.85 |
| 149 | Spinocerebellar ataxia 45 | Enrichment | FH | 1.85 |
| 150 | Mitochondrial dna depletion syndrome 15 | Enrichment | TFAM | 1.85 |
| 151 | Nuclear type mitochondrial complex i deficiency | Enrichment | NDUFV1 | 1.85 |
| 152 | Mitochondrial complex i deficiency, nuclear type 13 | Enrichment | NDUFA2 | 1.85 |
| 153 | Normal pressure hydrocephalus | Enrichment | PMPCA | 1.85 |
| 154 | D-2-hydroxyglutaric aciduria | Enrichment | IDH2 | 1.85 |
| 155 | Autosomal erythropoietic protoporphyria | Enrichment | FECH | 1.85 |
| 156 | Erythropoietic protoporphyria, autosomal recessive | Enrichment | FECH | 1.85 |
| 157 | Periodic paralysis with later-onset distal motor neuropathy | Enrichment | MT-ATP6 | 1.85 |
| 158 | Tetralogy of fallot | Enrichment | MT-CO1, MT-CO2 | 1.84 |
| 159 | Auditory neuropathy | Enrichment | MT-ND6, OPA1 | 1.84 |
| 160 | Keratoderma, palmoplantar, with deafness | Enrichment | MT-CO1 | 1.68 |
| 161 | Maple syrup urine disease, type ia | Enrichment | DBT | 1.68 |
| 162 | Mitochondrial complex iv deficiency, nuclear type 5 | Enrichment | ATP5F1A | 1.68 |
| 163 | Spinocerebellar ataxia, autosomal recessive 2 | Enrichment | PMPCA | 1.68 |
| 164 | Mitochondrial dna depletion syndrome 7 | Enrichment | TWNK | 1.68 |
| 165 | Spastic paraplegia 7, autosomal recessive | Enrichment | SPG7 | 1.68 |
| 166 | Glaucoma, normal tension | Enrichment | OPA1 | 1.68 |
| 167 | Infantile cerebellar-retinal degeneration | Enrichment | ACO2 | 1.68 |
| 168 | Optic atrophy 9 | Enrichment | ACO2 | 1.68 |
| 169 | Mitochondrial complex v deficiency, nuclear type 7 | Enrichment | ATP5PO | 1.68 |
| 170 | Chronic progressive external ophthalmoplegia | Enrichment | TWNK | 1.68 |
| 171 | Autosomal dominant cutis laxa | Enrichment | ALDH18A1 | 1.68 |
| 172 | Hyperinsulinemic hypoglycemia | Enrichment | HADH | 1.68 |
| 173 | Cerebellar disease | Enrichment | AFG3L2 | 1.68 |
| 174 | Anaplastic astrocytoma | Enrichment | IDH2 | 1.68 |
| 175 | Mitochondrial complex v deficiency, nuclear type 1 | Enrichment | NDUFS1 | 1.68 |
| 176 | Gonadal dysgenesis | Enrichment | MT-ATP6 | 1.68 |
| 177 | 3-methylglutaconic aciduria | Enrichment | YME1L1 | 1.68 |
| 178 | Mitochondrial complex i deficiency, nuclear type 28 | Enrichment | NDUFA13 | 1.68 |
| 179 | Myelodysplastic syndrome with ring sideroblasts | Enrichment | MT-CO1 | 1.68 |
| 180 | Autosomal dominant optic atrophy, classic form | Enrichment | OPA1 | 1.68 |
| 181 | Intermittent maple syrup urine disease | Enrichment | DBT | 1.68 |
| 182 | Classic maple syrup urine disease | Enrichment | DBT | 1.68 |
| 183 | Cardiomyopathy, infantile histiocytoid | Enrichment | MT-ATP6 | 1.55 |
| 184 | Propionic acidemia | Enrichment | PCCB | 1.55 |
| 185 | Mitochondrial complex v deficiency, nuclear type 3 | Enrichment | UQCRC2 | 1.55 |
| 186 | Hereditary recurrent myoglobinuria | Enrichment | MT-CO1 | 1.55 |
| 187 | 3-methylglutaconic aciduria, type viii | Enrichment | HTRA2 | 1.55 |
| 188 | Intermediate maple syrup urine disease | Enrichment | DBT | 1.55 |
| 189 | Familial infantile bilateral striatal necrosis | Enrichment | MT-ATP6 | 1.55 |
| 190 | Enchondromatosis, multiple, ollier type | Enrichment | IDH2 | 1.46 |
| 191 | 3-methylglutaconic aciduria, type iii | Enrichment | OPA1 | 1.46 |
| 192 | Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis | Enrichment | TWNK | 1.46 |
| 193 | Mitochondrial complex iii deficiency, nuclear type 4 | Enrichment | UQCRQ | 1.46 |
| 194 | Polyneuropathy | Enrichment | SPG7 | 1.46 |
| 195 | Familial glucocorticoid deficiency | Enrichment | STAR | 1.46 |
| 196 | Hereditary spastic paraplegia | Enrichment | ALDH18A1, SPG7 | 1.45 |
| 197 | Hypertrophic cardiomyopathy | Enrichment | NDUFA13, PMPCA | 1.43 |
| 198 | Alcohol dependence | Enrichment | ALDH2 | 1.38 |
| 199 | Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 | Enrichment | TWNK | 1.38 |
| 200 | Multiple enchondromatosis, maffucci type | Enrichment | IDH2 | 1.31 |
| 201 | Third-degree atrioventricular block | Enrichment | TWNK | 1.31 |
| 202 | Alzheimer's disease 1 | Enrichment | APP | 1.31 |
| 203 | Parkinsonism | Enrichment | MT-ND6 | 1.31 |
| 204 | Early-onset autosomal dominant alzheimer disease | Enrichment | APP | 1.31 |
| 205 | Spastic ataxia | Enrichment | AFG3L2, SPG7 | 1.27 |
| 206 | Hereditary retinal dystrophy | Enrichment | ACO2, IDH3A, MT-ND6, OPA1, SPG7 | 1.26 |
| 207 | Fundus dystrophy | Enrichment | ACO2, IDH3A, MT-ND6, OPA1, SPG7 | 1.26 |
| 208 | Glioma susceptibility 1 | Enrichment | IDH2 | 1.26 |
| 209 | Choreatic disease | Enrichment | AFG3L2 | 1.26 |
| 210 | Ellis-van creveld syndrome | Enrichment | PRKACA | 1.21 |
| 211 | Autosomal dominant cerebellar ataxia | Enrichment | OPA1 | 1.21 |
| 212 | Migraine with or without aura 1 | Enrichment | MT-ND1 | 1.12 |
| 213 | Myoclonic epilepsy associated with ragged-red fibers | Enrichment | MT-ND5 | 1.09 |
| 214 | Early-onset parkinson's disease | Enrichment | HTRA2 | 1.09 |
| 215 | Restrictive cardiomyopathy | Enrichment | MT-ND1 | 1.09 |
| 216 | Aortic valve disease 1 | Enrichment | MT-ATP6 | 1.05 |
| 217 | Diaphragmatic hernia, congenital | Enrichment | LONP1 | 1.05 |
| 218 | Lipoid congenital adrenal hyperplasia | Enrichment | STAR | 1.02 |
| 219 | Cataract | Enrichment | IARS2 | 1.02 |
| 220 | Hereditary chronic pancreatitis | Enrichment | SPG7 | 1.02 |
| 221 | Isolated macular dystrophy | Enrichment | ACO2 | 1.02 |
| 222 | Hydrocephalus, congenital, 1 | Enrichment | MT-ND1 | 0.97 |
| 223 | Pancreatitis, hereditary | Enrichment | SPG7 | 0.94 |
| 224 | Colorectal cancer | Enrichment | MT-CO1, MT-ND1 | 0.90 |
| 225 | Parkinson's disease | Enrichment | MT-ND1 | 0.90 |
| 226 | Leukodystrophy | Enrichment | HSPD1 | 0.88 |
| 227 | Centronuclear myopathy | Enrichment | OPA1 | 0.86 |
| 228 | Hepatocellular carcinoma | Enrichment | FH | 0.84 |
| 229 | Attention deficit-hyperactivity disorder | Enrichment | MT-ND1 | 0.84 |
| 230 | Parkinson disease, late-onset | Enrichment | MT-ND1 | 0.80 |
| 231 | Developmental and epileptic encephalopathy 1 | Enrichment | MDH2 | 0.79 |
| 232 | Differentiated thyroid carcinoma | Enrichment | NDUFA13 | 0.73 |
| 233 | Stargardt disease 1 | Enrichment | OPA1 | 0.72 |
| 234 | Peripheral nervous system disease | Enrichment | IARS2 | 0.69 |
| 235 | Neuropathy | Enrichment | IARS2 | 0.69 |
| 236 | Leukemia, acute myeloid | Enrichment | IDH2 | 0.61 |
| 237 | Charcot-marie-tooth disease | Enrichment | MT-ATP6 | 0.60 |
| 238 | West syndrome | Enrichment | MDH2 | 0.57 |
| 239 | Sensorineural hearing loss | Enrichment | AFG3L2 | 0.54 |
| 240 | Cone-rod dystrophy 2 | Enrichment | SSBP1 | 0.42 |
| 241 | Rare genetic deafness | Enrichment | MT-ND1 | 0.37 |
| 242 | Ovarian cancer | Enrichment | FH | 0.29 |
| 243 | Congenital nervous system abnormality | Enrichment | ALDH18A1 | 0.28 |
| 244 | Nervous system disease | Enrichment | ALDH18A1 | 0.28 |
| 245 | Microcephaly | Enrichment | ATP5PO | 0.23 |
| 246 | Inherited cancer-predisposing syndrome | Enrichment | FH | 0.21 |